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Bovine Leukemia Virus (BLV), a Deltaretrovirus in the
Retroviridae family, is the causative agent of Enzootic
Bovine Leucosis (EBL). Whilst EBL is still endemic in the
Americas and Eastern Europe, most Western European
countries are disease free in accordance with European
Union legislation e.g. Great Britain has held EBL-free
status since 1999. BLV infection is life-long and the pre-
sence of antibody and integrated proviral DNA are indi-
cators of exposure to the virus.Screening for antibodies is
the primary means of diagnosis. Here we present three
case reports of animals which tested BLV antibody posi-
tive. As there was no evidence that the animals or their
in-contacts were infected with BLV the result was some-
what confusing. Investigation revealed that the animals
had been fed a colostrum replacer that was produced
outside of Great Britain. As BLV is endemic in some
countries, it was considered that BLV antibodies may
have been present in the colostrum replacer and thus
passively acquired resulting in BLV sero-positivity. The
hypothesis was supported by the declining serological
antibody titre seen on serial blood sampling. We present
data on the serological and molecular testing conducted
on the animals and product in support of the hypothesis.
The above mentioned cases were all linked by the same
brand of colostrum replacer; in addition we provide data
derived from the investigation of colostrum replacers
from other manufacturers. The policy and International
Trade implications will also be discussed.
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